Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Cholestasis due to biliary obstruction can cause cardiogenic shock with bradycardia by delaying the elimination of arotinolol.
BMJ Case Rep
January 2025
Critical Care Medicine, Metropolitan Bokutoh Hospital, Tokyo, Japan.
Cardiogenic shock with bradycardia due to beta-blockers is well-documented; however, this condition in association with arotinolol is unreported. We present a case of cardiogenic shock resulting from delayed arotinolol clearance caused by bile duct obstruction. A man in his 60s presented to our hospital with jaundice.
View Article and Find Full Text PDFAtomoxetine-Induced Pheochromocytoma and Paraganglioma Crisis Managed With Veno-Arterial Extracorporeal Membrane Oxygenation.
Cureus
November 2024
Department of Emergency and Critical Care Medicine, Tokai University School of Medicine, Isehara, JPN.
Pheochromocytoma and paragangliomas (PPGLs) crises can be triggered by various factors, including norepinephrine reuptake inhibitors used to treat attention deficit hyperactivity disorder (ADHD), which worsen symptoms in patients with PPGLs. Therefore, attention should be paid to the potential for serious adverse reactions in patients with PPGLs taking ADHD medications. A 21-year-old man presented to the emergency department with acute onset of severe respiratory and circulatory failure after initiating atomoxetine treatment.
View Article and Find Full Text PDFEfficacy and Safety of Ivabradine for Patients With Acute Heart Failure: Meta-Analysis of Randomized Controlled Trials.
Ann Noninvasive Electrocardiol
November 2024
Department of Cardiology, The First Hospital of Jilin University, Changchun, China.
Introduction: The efficacy and safety of Ivabradine for patients with acute heart failure (AHF) is controversial, and there are few clinical trials addressing this topic.
Methods: We performed this meta-analysis to evaluate efficacy and safety of Ivabradine treatment for patients with acute heart failure. We obtained data for controlled trials using the PubMed, Cochrane Library, EMBASE, and Clinical Trials.
Immune checkpoint inhibitor-associated sick sinus syndrome and cardiogenic shock.
Int Cancer Conf J
October 2024
Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, 3-18-22 Honkomagome, Bunkyo-Ku, Tokyo 113-8677 Japan.
Article Synopsis
- Immune checkpoint inhibitors (ICI) have significantly improved cancer treatment, but they often have underestimated side effects, particularly related to heart health.
- A case study highlighted a 67-year-old Japanese man who experienced severe heart issues, including cardiogenic shock and sick sinus syndrome, shortly after starting a combination therapy with ipilimumab and nivolumab.
- To manage his condition, doctors first used a temporary pacemaker, followed by the implantation of a permanent pacemaker, which relieved his symptoms and enabled him to continue cancer treatment.
Safety and efficacy of early beta-blocker initiation in acute heart failure and cardiogenic shock: systematic review and meta-analysis.
Egypt Heart J
September 2024
Faculty of Medicine, Udayana University/Prof. Dr. I.G.N.G Ngoerah General Hospital, Denpasar, Bali, Indonesia.
Article Synopsis
- This study investigates the safety and effectiveness of starting beta-blocker (BB) therapy in patients hospitalized for acute heart failure (AHF), focusing on both in-hospital and long-term outcomes.
- Results from eight studies with over 16,000 patients indicated that early BB initiation significantly lowered in-hospital complications, overall mortality during hospitalization, mortality at discharge, and rates of rehospitalization compared to a control group.
- The findings suggest that initiating beta-blocker treatment in AHF patients is both beneficial in terms of efficacy and safe, as there were no significant negative side effects observed between the groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!